Exelixis Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Great. So it's Michael Schmidt, Senior biotech analyst with Guggenheim. It is my great pleasure to welcome the next presenting company, Exelixis. With us today, we have Peter Lamb, Head of R&D or EVP of Scientific Strategy -- I'm sorry, as well as Andrew Peters, SVP of Strategy. Welcome, guys, and thanks for joining us.
Thanks for having us.
Questions & Answers
All right. So we'll jump right into the Q&A fireside chat. Starting with the commercial question. Obviously, Cabo has been tremendously successful with over $1.4 billion in net sales last year, and you've provided guidance recently for this year of $1.575 billion to $1.675 billion. Maybe, Andrew, could you remind us of the sort of the primary growth drivers for CABOMETYX sales in 2022?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
